The Pathologist in the Era of Immunotherapy

Presented by

Dr. Ken Bloom

About this talk

The job of the pathologist is crucial in the era of precision medicine and immunotherapy. Pathologists need not only to correctly diagnose and classify tumors, but also aid in the selection of the best treatment strategies based on the presence or absence of critical biomarkers. Because tumors are heterogeneous, this includes discussion with the interventionalist about which lesions to sample in metastatic disease and selection of the best area of tumor for analysis in resections. While next generation sequencing techniques provide a plethora of data about mutations, gene expression and copy number, the pathologist must interpret these results in the context of the histologic appearance of the sample. In this webinar, Dr. Bloom will review the challenges faced by pathologists today with the emergence of immunotherapy and explain the critical role of the pathologist in assessing the tumor and its microenvironment.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (63)
Subscribers (8307)
This series is brought to you by Roche. We are committed to providing you with educational content, from key opinion leaders, related to personalized diagnostics. We aim to ensure on ongoing conversation is taking place in this evolving area of healthcare. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit